Results 221 to 230 of about 144,436 (251)

Immune checkpoint inhibitor myocarditis

Current Opinion in Cardiology, 2019
The purpose of this study is to summarize and highlight the recent literature regarding immune checkpoint inhibitor myocarditis.The use of immune checkpoint inhibitors, a promising form of immunotherapy, is rapidly increasing in oncology. These drugs have been recently found to cause a fulminant myocarditis associated with a high-case fatality rate ...
Jayant, Raikhelkar, Nir, Uriel
openaire   +2 more sources

Immune Checkpoint Inhibitors in Gliomas

Current Oncology Reports, 2017
Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise.A limited body of preclinical evidence suggests that checkpoint inhibitors may be effective ...
Aaron C, Tan, Amy B, Heimberger, Mustafa, Khasraw   +2 more
openaire   +2 more sources

Radiotherapy, immunity, and immune checkpoint inhibitors

The Lancet Oncology
Radiotherapy exerts immunostimulatory and immunosuppressive effects, both locally, within the irradiated tumour microenvironment, and systemically, outside the radiation field. Inspired by preclinical data that showed synergy between radiotherapy and immune checkpoint inhibitors, multiple clinical trials were initiated with the hypothesis that combined
Connor, Lynch, Sean P, Pitroda, Ralph R, Weichselbaum   +2 more
openaire   +2 more sources

Melanoma and Immune Checkpoint Inhibitors

Current Oncology Reports, 2018
Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients.
Masutaka, Furue, Takamichi, Ito, Naoko, Wada, Maiko, Wada, Takafumi, Kadono, Hiroshi, Uchi   +5 more
openaire   +2 more sources

Immune Checkpoint Inhibitors in Cholangiocarcinoma

Immunotherapy, 2023
Cholangiocarcinoma is an epithelial malignancy originating in the biliary tracts and frequently recurs even with surgical resection. Unresectable disease has a 5-year overall survival of less than 10%. Given this poor prognosis, additional therapies are urgently needed. Chemotherapy has been the mainstay of treatment for many years.
openaire   +2 more sources

Immune Checkpoint Inhibitor–Induced Lipodystrophy

JAMA Dermatology
This case series describes lipodystrophy, a rare adverse event associated with immune checkpoint inhibitor therapy.
Riganti J., Torre A. C., Sollena P., Koumaki D., Freites-Martinez A., Delyon J., Communie A., Starace M., Rapparini L., Lallas A., Mavroudis D., Suzanne D., Mazzuoccolo L. D., Bobos M., Sibaud V., Apalla Z.   +15 more
openaire   +3 more sources

Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment

Cell, 2023
Steven J Mullett, Marlies Meisel
exaly  

Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes

Ocular Immunology and Inflammation, 2021
Madeline Yung, Edmund Tsui
exaly  

Immune checkpoint inhibitors

Reactions Weekly, 2020
  +5 more sources

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment

Journal of Clinical Endocrinology and Metabolism, 2021
Christopher A Muir, Roderick Clifton-Bligh, Georgina V Long   +2 more
exaly